

# Semaglutide & Weight Loss: Examining the Science, Media Controversies, & Clinical Implications

Tuesday November 12<sup>th</sup> 2024, 12:30 – 1:30pm

Via WebEx

Target Audience: All healthcare professionals, healthcare educators and researchers.

Activity Code: AGI-03-P185

**Aim:** To provide health professionals with a comprehensive understanding of the increased use of semaglutide and other GLP-1 receptor agonists for weight loss. The session will address recent controversies and debates highlighted in both the media and peer-reviewed literature, equipping participants with the knowledge to make informed clinical decisions and address patient concerns.

## Overall learning objectives:

- Discuss the mechanism of action of semaglutide and similar drugs in weight loss.
- Examine the efficacy and safety data from recent clinical trials and peer-reviewed studies.
- Analyze the ethical and practical controversies surrounding the use of these drugs, including media portrayal and patient access.
- Discuss evidence-based recommendations for health professionals considering semaglutide for weight management in their practice.

## Speakers

**Dr Mohsen Eledrisi**, Senior Consultant Physician, Department of Medicine, Hamad Medical Corporation.

**Dr Mohamed Salem Abdelgelil**, Clinical pharmacy specialist at Hamad Medical Corporation.

## Moderator

**Dr Hazem Elewa**, Associate Professor, PharmD Director, College of Pharmacy, Qatar University

\* The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.

\* "This activity is an Accredited group learning activity (Category 1) as defined by Ministry of Public Health's Department of Healthcare Professions - Accreditation Section and is approved for a maximum number of 1 Hours."

\* "CPD-HP (QU—Health) is accredited by Ministry of Public Health's Department of Healthcare Professions - Accreditation Section (DHP – AS) as a provider of continuing professional development."

Activity schedule:

Time & Speaker	Schedule	Learning objective(s)
12:30 – 12:35	Welcoming and introduction	
12:35 - 12:50 Dr Mohamed Abdelgelil	<b>Overview of Semaglutide and GLP-1 Agonists for Weight Loss</b>	Discuss the mechanism of action of semaglutide and similar drugs in weight loss.
12:50 – 13:05 Dr Mohsen Eledrisi	<b>Efficacy and Safety: What the Latest Evidence Says</b>	Examine the efficacy and safety data from recent clinical trials and peer-reviewed studies.
13:05 – 13:25 All panelists	<b>Panel Discussion &amp; Live Q&amp;A: Addressing Media Controversies and Ethical Considerations</b>	Analyze the ethical and practical controversies surrounding the use of these drugs, including media portrayal and patient access.  Discuss evidence-based recommendations for health professionals considering semaglutide for weight management in their practice.
13:25 - 13:30	Post-activity evaluation	